Pfizer Repositioning Itself

 

Several weeks ago there was news that  Pfizer, the maker of Lipitor, was buying  King Pharmaceutical.   The financial analyst commented that they were making this  3.6 billion dollar deal to help off set the predicted decline in income when their blockbuster drug Lipitor goes generic.

Well, in addition to this multi-billion dollar cash purchase, Pfizer is also attempting to capture another market – our children.     They have come out with a chewable Lipitor for children over 10 years of age. To help drive sales of this new product, The Journal of Pediatrics is urging physicians to do cholesterol screening for all children.

So in addition to putting millions of adults on this dangerous statin drug, Pfizer with the help of the medical community, also want to target our children.

Terry Pfau, DO, HMD

Scroll to Top